1
|
Tiemi Enokida Mori M, Name Colado Simão A, Danelli T, Rangel Oliveira S, Luis Candido de Souza Cassela P, Lerner Trigo G, Morais Cardoso K, Mestre Tejo A, Naomi Tano Z, Regina Delicato de Almeida E, Maria Vissoci Reiche E, Maes M, Alysson Batisti Lozovoy M. Protective effects of IL18-105G > A and IL18-137C > Ggenetic variants on severity of COVID-19. Cytokine 2024; 174:156476. [PMID: 38128426 DOI: 10.1016/j.cyto.2023.156476] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/29/2023] [Accepted: 12/08/2023] [Indexed: 12/23/2023]
Abstract
OBJECTIVE AND DESIGN A cross-sectional study evaluated the IL18-105G > A (rs360717) and IL18-137C > G (rs187238) variants on Coronavírus Disease 2019 (COVID-19) severity. SUBJECTS AND METHODS 528 patients with COVID-19 classifed with mild (n = 157), moderate (n = 63) and critical (n = 308) disease were genotpyed for the IL18-105G > A and IL18-137C > G variants. RESULTS We observed associations between severe + critical COVID-19 groups (reference group was mild COVID-19) and the IL18-105G > A (p = 0.008) and IL18-137C > G (p = 0.01) variants, which remained significant after adjusting for sex, ethnicity and age. Consequently, we have examined the associations between moderate + critical COVID-19 and the genotypes of both variants using different genetic models. The IL18-105G > A was associated with severe disease (moderate + critical), with effects of the GA genotype in the codominant [Odds ratio (OR), (95 % confidence interval) 0.55, 0.34-0.89, p = 0.015], overdominant (0.56, 0.35-0.89, p = 0.014) and dominant (0.60, 0.38-0.96, p = 0.031) models. IL18-105 GA coupled with age, chest computed tomograhy scan anormalities, body mass index, heart diseases, type 2 diabetes mellitus, hypertension, and inflammation may be used to predict the patients who develop severe disease with an accuracy of 84.3 % (sensitivity: 83.3 % and specificity: 86.5 %). Therefore, the presence of the IL18-105 A allele in homozygosis or heterozygosis conferred about 44.0 % of protection in the development of moderate and severe COVID-19. The IL18-137C > G variant was also associated with protective effects in the codominant (0.55, 0.34-0.89, p = 0.015), overdominant (0.57, 0.36-0.91, p = 0.018), and dominant models (0.59, 0.37-0.93, p = 0.025). Therefore, the IL18-137 G allele showed a protective effect against COVID-19 severity. CONCLUSION The IL18-105G > A and IL18-137C > Gvariants may contribute with protective effects for COVID-19 severity and the effects of IL18-137C > G may be modulating IL-18 production and Th1-mediated immune responses.
Collapse
Affiliation(s)
| | - Andréa Name Colado Simão
- Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil; Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil.
| | - Tiago Danelli
- Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil
| | - Sayonara Rangel Oliveira
- Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil
| | | | - Guilherme Lerner Trigo
- Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil
| | - Kauê Morais Cardoso
- Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil.
| | | | - Zuleica Naomi Tano
- Depertment of Medical Clinic, University of Londrina, Londrina, PR, Brazil.
| | - Elaine Regina Delicato de Almeida
- Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil; Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil
| | - Edna Maria Vissoci Reiche
- Postgraduate Program of Clinical and Laboratory Pathophysiology, Health Sciences Center, Londrina State University, Lodrina, Paraná, Brazil; Pontifical Catholic University of Paraná, School of Medicine, Campus Londrina, Lonidrna, Paraná, Brazil.
| | - Michael Maes
- Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu 610072, China.
| | - Marcell Alysson Batisti Lozovoy
- Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil; Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research in Applied Immunology, University of Londrina, Londrina, PR, Brazil
| |
Collapse
|
2
|
Colado Simão AN, Perugini Stadtlober N, Stinghen Garcia Lonni AA, Venâncio LM, Lerner Trigo G, de Souza Cassela PLC, Mastellini Sanches Silva T, De Fátima Oliveira Hirth Ruiz M, Batisti Lozovoy MA, Tano ZN, da Fonseca Orcina B, Vieira Vilhena F, da Silva Santos PS. Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial. Ger Med Sci 2023; 21:Doc07. [PMID: 37426884 PMCID: PMC10326526 DOI: 10.3205/000321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 11/16/2022] [Indexed: 07/11/2023]
Abstract
Background In individuals with coronavirus disease (COVID-19), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL) plays an important role in infectivity. Objectives This study aimed to evaluate the reduction in the VL and infectivity induced by phthalocyanine mouthwash and nasal spray in patients with COVID-19. Methods Patients with mild COVID-19 were recruited to participate in a triple-blinded randomized controlled trial. Participants were assigned to one of three groups: Group 1, non-active mouthwash and saline nasal spray (SNS); Group 2, phthalocyanine mouthwash and SNS; and Group 3 phthalocyanine mouthwash and phthalocyanine nasal spray. VL was assessed in nasopharyngeal and oropharyngeal swabs collected at the time of clinical diagnosis at baseline as well as 24 and 72 hours after starting the rinsing protocols. Findings Forty-six participants were included in the analysis: 15, 16, and 15 in Groups 1, 2, and 3, respectively. After 72 hours, the reduction in VL was significantly higher in Group 3 (mean cycle threshold (Ct) decrease: 11.21) than in Group 1 (mean Ct decrease: 5.53). Additionally, only the mean VL in Group 3 was reduced to a non-contagious level after 72 hours. Main conclusions Use of phthalocyanine mouthwash and nasal spray is effective at reducing SARS-CoV-2 infectivity.
Collapse
Affiliation(s)
| | | | | | - Luiza Mara Venâncio
- Research Laboratory in Applied Immunology, State University of Londrina, Brazil
| | | | | | | | | | | | - Zuleica Naomi Tano
- Research Laboratory in Applied Immunology, State University of Londrina, Brazil
| | - Bernardo da Fonseca Orcina
- Department of Surgery, Stomatology, Pathology and Radiology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil
| | | | - Paulo Sérgio da Silva Santos
- Department of Surgery, Stomatology, Pathology and Radiology, Bauru School of Dentistry, University of São Paulo, Bauru, Brazil
| |
Collapse
|
3
|
Ivanski F, Fermino BL, Cassela PLCDS, Buss CE, Zueli KCP, Oliveira IMD, Simão ANC, Boldt ABW, Figueiredo DLA, Carraro E. ESTUDO DA ASSOCIAÇÃO DE POLIMORFISMOS GENÉTICOS DA IL-18 NA COVID-19. Braz J Infect Dis 2022. [PMCID: PMC9461061 DOI: 10.1016/j.bjid.2022.102593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Introdução Há evidências da associação da gravidade da COVID-19 com níveis séricos elevados da interleucina-18 (IL-18), as variantes genéticas desta citocina podem influenciar sua expressão e níveis séricos, contribuindo para a gravidade da COVID-19, há poucos estudos que correlacionam os polimorfismos genéticos da IL-18 com a gravidade desta doença, por isso buscamos contribuir para a compreensão da heterogeneidade clínica e desfecho em uma amostra da população brasileira de pacientes com COVID-19. Objetivo Avaliar a associação dos polimorfismos no gene da IL-18 com a gravidade clínica e desfecho da COVID-19 em uma amostra do estado do Paraná (PR). Método O estudo incluiu 158 pacientes de ambos os sexos, que recorreram ao serviço de atendimento hospitalar no período de junho a novembro de 2020 e que testaram positivo para SARS-CoV-2/RT-PCR+. Foram incluídos pacientes advindos da Universidade Estadual do Centro Oeste (UNICENTRO) de Guarapuava; da Universidade Estadual de Londrina (UEL) em Londrina e da Pontifícia Universidade Católica do Paraná (PUCPR) em Curitiba. As análises moleculares foram realizadas no Instituto para Pesquisa do Câncer (IPEC) de Guarapuava - PR. A coorte foi composta por 3 grupos e a estratificação dos casos foi feita por gravidade, conforme critérios estabelecidos pela Organização Mundial da Saúde. Resultados Avaliamos as variantes da IL-18 associados a gravidade da COVID-19 (casos leves x casos moderados e graves) e obtivemos os seguintes polimorfismos: rs360721 (alelos: C/G /freq: 0.22/ OR 1.603 (0.849; -3.026)/p: 0.1456), rs549908 (alelos: G/T /freq: 0.22/ OR 1.285 (0.6617; -2.496)/p: 0.4588), rs45497197 (alelos: T/C /freq: 0.01/ OR 0.2173 (0.01918; -2.463)/p: 0.2179), rs147751347 (alelos: T/G /freq: 0.02/ OR 1.532 (0.3591; -6.539)/p: 0.5643), rs141025779 (alelos: A/G / freq: 0.02/ OR 1.657 (0.3826; - 7.178)/ p: 0.4994), rs4988359 (alelos: C/T / freq: 0.14 / OR 1.166 (0.5261; -2.584)/p: 0.7052). Consideramos também a associação entre o desfecho clínico (recuperados x óbitos), neste cenário encontramos apenas uma variante: rs549908 (alelos: G/T / freq: 0.22 / OR 0.2556 (0.08; - 0.78)/p: 0.01757). Conclusão Esses achados sugerem que a variante do gene da IL-18, rs549908, está associado ao desfecho clínico da COVID-19 e que são necessários mais estudos para avaliar importância das variantes genéticas do gene da IL-18 como marcadores de prognóstico na doença. Ag. Financiadora Fundação Araucária.
Collapse
|